Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report

Hong Zhu, Xi Yang, Yaqin Zhao, Cheng Yi, Hong Zhu, Xi Yang, Yaqin Zhao, Cheng Yi

Abstract

Rationale: Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is an aggressive tumor with very poor prognosis. Regorafenib was the first agent to show a survival benefit over placebo in patients who showed progression while being treated with sorafenib, but it remains an unsatisfactory agent owing to its serious side effects. Therefore, more efficient and milder therapies are needed.

Patient concerns: Herein, we report a patient with advanced HCC with many lung metastases who showed progression during sorafenib treatment.

Diagnoses: HCC with lung metastases (stage IVB).

Interventions: SHR-1210 alone was used as second-line treatment.

Outcomes: Although the lung metastases did not decrease 3 months after the treatment, they decreased significantly at 6 months after the treatment and partially disappeared. The tumor response indicated partial response. Furthermore, all of the lung metastases continued to decrease at about 17 months after treatment. The alpha-fetoprotein levels showed a similar trend. After a follow up of 19 months, the patient remains in good health.

Lessons: SHR-1210 alone as a second-line treatment for a patient with HCC showed excellent antitumor effects. We think that SHR-1210 may exert its antitumor effects through a late-onset model, which persist for a long time. The side effects were mild and well tolerated.

Figures

Figure 1
Figure 1
(A) The liver before SHR-1210 treatment (July 23, 2017). (B) The liver 3 months after SHR-1210 treatment (November 29, 2017). (C) The liver 6 months after SHR-1210 treatment (February 26, 2018). (D) The liver about 17 months after SHR-1210 treatment (January 18, 2019).
Figure 2
Figure 2
(A) The lung metastases before SHR-1210 treatment (July 23, 2017). (B) The lung metastases 3 months after SHR-1210 treatment (November 29, 2017). (C) The lung metastases 6 months after SHR-1210 treatment (February 26, 2018). (D) The lung metastases about 17 months after SHR-1210 treatment (January 18, 2019).
Figure 3
Figure 3
(A) The lung metastases before SHR-1210 treatment (July 23, 2017). (B) The lung metastases 3 months after SHR-1210 treatment (November 29, 2017). (C) The lung metastases 6 months after SHR-1210 treatment (February 26, 2018). (D) The lung metastases about 17 months after SHR-1210 treatment (January 18, 2019).
Figure 4
Figure 4
(A) The lung metastases before SHR-1210 treatment (July 23, 2017). (B) The lung metastases 3 months after SHR-1210 treatment (November 29, 2017). (C) The lung metastases 6 months after SHR-1210 treatment (February 26, 2018). (D) The lung metastases about 17 months after SHR-1210 treatment (January 18, 2019).
Figure 5
Figure 5
(A) The lung metastases before SHR-1210 treatment (July 23, 2017). (B) The lung metastases 3 months after SHR-1210 treatment (November 29, 2017). (C) The lung metastases 6 months after SHR-1210 treatment (February 26, 2018). (D) The lung metastases about 17 months after SHR-1210 treatment (January 18, 2019).
Figure 6
Figure 6
(A) The lung metastases before SHR-1210 treatment (July 23, 2017). (B) The lung metastases 3 months after SHR-1210 treatment (November 29, 2017). (C) The lung metastases 6 months after SHR-1210 treatment (February 26, 2018). (D) The lung metastases about 17 months after SHR-1210 treatment (January 18, 2019).

References

    1. Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599–616.
    1. Qin S, Kruger E, Tan SC, et al. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc 2018;16:29.
    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
    1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
    1. Zhu H, Ma X, Zhao Y, et al. The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: a case report. Medicine 2018;97:e11214.
    1. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56–66.
    1. Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacol Ther 2019;194:84–106.
    1. Dermani FK, Samadi P, Rahmani G, et al. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol 2018;2019:1313–25.
    1. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–502.
    1. Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res 2018;24:1296–304.
    1. Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018;19:1338–50.
    1. Morano F, Corallo S, Niger M, et al. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Ann Oncol 2018;29:1800–6.
    1. Zhu H, Zhao Y, Wang X. The radiosensitive effect of apatinib for hepatocellular carcinoma patient with big paraspinal metastasis: a case report. Medicine 2018;97:e9598.
    1. Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer 2018;119:538–45.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit